Paper Details

  1. Home
  2. Paper Details

Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.

Author: CatarigAndrei-Mircea, FriasJuan P, LausvigNanna L, LingvayIldiko, McCrimmonRory J, ThielkeDesirée, le RouxCarel W

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Semaglutide and canagliflozin both effectively reduced body fat mass, but semaglutide showed greater reductions in visceral fat mass compared to canagliflozin.
Paper Details　
Original Abstract of the Article :
Intra-abdominal or visceral obesity is associated with insulin resistance and an increased risk for cardiovascular disease. This study aimed to compare the effects of semaglutide 1.0 mg and canagliflozin 300 mg on body composition in a subset of participants from the SUSTAIN 8 Phase IIIB, randomised...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997246/

データ提供：米国国立医学図書館（NLM）

Semaglutide vs. Canagliflozin: A Battle for Body Composition in Type 2 Diabetes

Type 2 diabetes, a growing health concern, often involves challenges with weight management and body composition. This study compares the effects of two medications, semaglutide and canagliflozin, on body composition in patients with type 2 diabetes. It's like a desert expedition, exploring the different approaches to managing weight and improving overall health.

A Tale of Two Medications: Semaglutide and Canagliflozin

The study found that semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, was more effective than canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in reducing intra-abdominal fat. This finding suggests that semaglutide may offer a more targeted approach to managing visceral obesity, a key risk factor for cardiovascular disease. It's like choosing the right tool for the job - semaglutide might be the better choice for addressing the specific challenge of visceral fat.

A Choice for Better Health

This research provides valuable insights into the different effects of semaglutide and canagliflozin on body composition. The findings suggest that semaglutide might be a more effective option for managing visceral obesity and improving cardiovascular health. It's a reminder that the desert of type 2 diabetes management is diverse, and choosing the right treatment strategy is crucial for achieving optimal health outcomes.

Dr. Camel's Conclusion

The comparison of semaglutide and canagliflozin in this study offers valuable insights into the nuances of type 2 diabetes management. The findings highlight the importance of considering body composition and cardiovascular health when selecting medication. It's a reminder that the desert of type 2 diabetes is vast and complex, but with ongoing research and personalized treatment approaches, we can find better ways to manage the disease and improve the well-being of those affected.

Date :
  1. Date Completed 2021-04-01
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

31897524

DOI: Digital Object Identifier

PMC6997246

Related Literature

Article Analysis
・Effects of semaglutide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.